Avadel Pharmaceuticals Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Avadel Pharmaceuticals Plc (AVDL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Avadel Pharmaceuticals Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 249M vs 44,838M combined for its competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+24.6% annualized vs trailing 12 months), vs decelerating (-4.4%) for its tracked peer group.
- Growth: Avadel Pharmaceuticals Plc generated 55.3% revenue growth year over year in Q3 2025, vs 11.7% for its competitors combined.
- Profitability: Its 0.0% net margin compares with 3.4% for the peer group.
- Peer revenue share: Avadel Pharmaceuticals Plc accounted for 0.7% of combined revenue among its tracked peer group, up from 0.5% a year earlier.
- Peer differentiation: Revenue per employee of $1.62M compares with $0.92M for the peer group (1.8x).
- Structure: Avadel Pharmaceuticals Plc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AVDL Sales vs. its Competitors, Q3 2025
Avadel Pharmaceuticals Plc reported revenue growth of 55.34 % year on year in Q3 2025, above its competitors' combined revenue growth of 11.66 %.
With a net margin of 0.03 %, Avadel Pharmaceuticals Plc reported lower profitability than its competitors (3.38 %).
Avadel Pharmaceuticals Plc generated 0.72 % of the combined sales of its peer group, up from 0.52 % a year earlier.
API endpoints for this dataset
Avadel Pharmaceuticals Plc vs. its Competitors, Q3 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Avadel Pharmaceuticals Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Avadel Pharmaceuticals Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Avadel Pharmaceuticals Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Avadel Pharmaceuticals Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 55.3% for Avadel Pharmaceuticals Plc. Avadel Pharmaceuticals Plc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Avadel Pharmaceuticals Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Avadel Pharmaceuticals Plc | No | Yes | Yes | No |
| Competitors combined (50) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AVDL Stock Performance relative to its Competitors
AVDL Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Evoke Pharma Inc | 282.9% | Outperformed |
| 2 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 3 | Jazz Pharmaceuticals Plc | 282.9% | Outperformed |
| 4 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Avadel Pharmaceuticals Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Avadel Pharmaceuticals Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Avadel Pharmaceuticals Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Avadel Pharmaceuticals Plc |
2,189.59 | 248.76 |
 Vertex Pharmaceuticals Inc |
140,582.02 | 12,951.60 |
 Insmed Inc |
25,401.29 | 1,479.04 |
 Jazz Pharmaceuticals Plc |
15,757.36 | 4,718.13 |
 Biomarin Pharmaceutical Inc |
11,069.48 | 3,655.13 |
 Praxis Precision Medicines Inc |
9,699.87 | 8.55 |
| SUBTOTAL | 235,130.69 | 45,303.24 |
Sign in to see all competitors of Avadel Pharmaceuticals Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Avadel Pharmaceuticals Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Avadel Pharmaceuticals Plc's Competitors Named by the Company
Competitive relationships identified from Avadel Pharmaceuticals Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Jazz Pharmaceuticals plc | Company report | 85% |
| Hikma Pharmaceuticals plc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Seelos Therapeutics inc | Company report | 85% |
| Aquestive Therapeutics Inc | Company report | 85% |
| Evoke Pharma Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Avadel Pharmaceuticals Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Avadel Pharmaceuticals Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Avadel Pharmaceuticals Plc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Insmed Inc | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Amneal Pharmaceuticals Inc | Affordable Medicines 58.61 % |
| Bausch Health Companies Inc | Bausch + Lomb 46.75 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Avadel Pharmaceuticals Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Avadel Pharmaceuticals Plc | 2,190 | 1,615,338 | -1,805 |
| Vertex Pharmaceuticals Inc | 140,582 | 31,979,259 | 9,817,037 |
| Insmed Inc | 25,401 | 888,846 | -363,948 |
| Jazz Pharmaceuticals Plc | 15,757 | 1,632,570 | 71,263 |
| Biomarin Pharmaceutical Inc | 11,069 | 1,134,780 | -5,934 |
| Praxis Precision Medicines Inc | 9,700 | 50,911 | -2,018,607 |
| PEERS TOTAL | 232,941 | 917,158 | -5,863 |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Avadel Pharmaceuticals Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Insmed Inc | United States 90.31 % |
| Jazz Pharmaceuticals Plc | United States 88.39 % |
| Ultragenyx Pharmaceutical Inc | North America 52.02 % |
| Aquestive Therapeutics Inc | United States 60.98 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Avadel Pharmaceuticals Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Avadel Pharmaceuticals Plc's industry classification, broader than the peer set above. Market cap in millions of $.Avadel Pharmaceuticals Plc ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,232,412 | 20.92 % |
| 2 | Johnson and Johnson | 679,690 | 11.54 % |
| 3 | Beone Medicines Ltd | 623,340 | 10.58 % |
| 4 | Abbvie Inc | 514,617 | 8.74 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Avadel Pharmaceuticals Plc | 2,192 | 0.00 % |
Market cap and industry share for the rest of Avadel Pharmaceuticals Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-02-11.
Avadel Pharmaceuticals Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 37.92 % (avg) | - |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 0.00 % | -6.19 % (avg) | +6.2 pp |
| Capital Intensity (Capex / Revenue) | - | 7.58 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Avadel Pharmaceuticals Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | 192.7x | 15.5x | +177.1x |
| P/B | 15.6x | 4.3x | +11.4x |
| Return on Equity | 0.00 % | industry aggregate | -17.61 % |
| Return on Invested Capital | - | -9.84 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Avadel Pharmaceuticals Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 287.25 % | - | - | - | - | - | - |
| Operating Margin | -3.09 % | - | -43.30 % | - | - | - | -25.11 % |
| Return on Invested Capital | -5.98 % | - | -14.72 % | - | -23.48 % | -79.80 % | -22.14 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Avadel Pharmaceuticals Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Avadel Pharmaceuticals Plc's dedicated Suppliers and Customers pages, not here.
Avadel Pharmaceuticals Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Avadel Pharmaceuticals Plc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Avadel Pharmaceuticals Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+24.6% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 17.6 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (44.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-4.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Avadel Pharmaceuticals Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Avadel Pharmaceuticals Plc | 1.14 | 2.76 | - |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Insmed Inc | 0.94 | 3.11 | 0.75 |
| Jazz Pharmaceuticals Plc | 0.81 | 1.87 | 1.27 |
| Biomarin Pharmaceutical Inc | 1.07 | 3.41 | 0.47 |
| Praxis Precision Medicines Inc | 11.53 | 11.58 | - |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Avadel Pharmaceuticals Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Avadel Pharmaceuticals Plc | Q3 2025 | +55.3 % | - |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Insmed Inc | Q3 2026 | +330.0 % | - |
| Jazz Pharmaceuticals Plc | Q3 2026 | +10.4 % | - |
| Biomarin Pharmaceutical Inc | Q3 2026 | +32.0 % | - |
| Praxis Precision Medicines Inc | Q2 2026 | - | - |
| PEERS TOTAL | +16.8 % | - |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Avadel Pharmaceuticals Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Avadel Pharmaceuticals Plc | Q3 2025 | -33.1 % | - |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Insmed Inc | Q3 2026 | +166.4 % | +132.6 % |
| Jazz Pharmaceuticals Plc | Q3 2026 | - | -64.1 % |
| Biomarin Pharmaceutical Inc | Q3 2026 | +46.6 % | -18.9 % |
| Praxis Precision Medicines Inc | Q2 2026 | - | +1,717.9 % |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
Avadel Pharmaceuticals Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Avadel Pharmaceuticals Plc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Insmed Inc | - | - | - |
| Jazz Pharmaceuticals Plc | 1.77% | 2.12% | 4.62% |
| Biomarin Pharmaceutical Inc | - | - | - |
| Praxis Precision Medicines Inc | - | - | - |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Avadel Pharmaceuticals Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Avadel Pharmaceuticals Plc | - | 8.80 |
| Vertex Pharmaceuticals Inc | 35.52 | 10.85 |
| Insmed Inc | - | 17.17 |
| Jazz Pharmaceuticals Plc | 79.33 | 3.34 |
| Biomarin Pharmaceutical Inc | - | 3.03 |
| Praxis Precision Medicines Inc | - | 1,134.09 |
| PEERS AVERAGE | - | 5.19 |
Sign in to see all peers for Avadel Pharmaceuticals Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.